A retrospective study analyzing outcomes of patients with anti-CD38 refractory myeloma

An analysis of survival outcomes in patients with triple-class refractory myelomaПодробнее

Outcomes of BCMA-exposed vs BCMA-naïve patients with R/R multiple myelomaПодробнее

Outcomes of patients who are BCMA-exposed versus BCMA-naïve in penta-R/R myelomaПодробнее

Anti-CD38 immunotherapy treatment for multiple myelomaПодробнее

Retrospective study on the outcomes of patients with myeloma treated with cilta-cel and ide-celПодробнее

Real-world analysis of patients with R/R myeloma treated with lenalidomide & an anti-CD38 mAbПодробнее

Outcomes of patients with triple-class refractory myeloma: a single-center retrospective studyПодробнее

The impact of the addition of anti-CD38 monoclonal antibodies to the frontline treatment of myelomaПодробнее

Mechanisms of action of CD38 antibodies in myelomaПодробнее

Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple MyelomaПодробнее

The Rise of Novel Antibodies in Multiple MyelomaПодробнее

Real-life analysis of myeloma patient survival in a third-level hospitalПодробнее

Dr. Noopur Raje Discusses Anti-CD38 Antibodies in MyelomaПодробнее

CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079Подробнее

Real-world Outcomes for Patients Treated with Ide-Cel after having Received a BCMA-targeted therapyПодробнее

Real-world treatment patterns in third-line therapy for R/R myelomaПодробнее

Optimising the management of multiple myeloma in the early relapsed/refractory settingПодробнее

Real-world analysis of treatment patterns and outcomes in newly diagnosed myelomaПодробнее

Improving outcomes for patients with R/R myelomaПодробнее